← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2012First marketed drug
Jul 3, 2019First NDA
Jul 3, 2019Last known activity
Dec 31, 2025
Timeline
Drugs by trial phase (68 distinct, 89 trials)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (35 own, 0 via acquisition)
Phase 1 (24 own, 0 via acquisition)
Indications
Studied for
- Aggression
- Blast Crisis
- Breast Neoplasms
- Carcinoma
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Communicable Diseases
- Coronavirus Infections
- Diabetic Foot
- Endometrial Neoplasms
- Foot Ulcer
- Glioblastoma
- Glioma
- Infections
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Prolymphocytic
- Liposarcoma
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Neoplasms, Plasma Cell
- Nerve Sheath Neoplasms
- Neurofibrosarcoma
- Polycythemia
- Polycythemia Vera
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Primary Myelofibrosis
- Prostatic Neoplasms
- Rectal Neoplasms
- Recurrence
- Sarcoma
- Sarcoma, Alveolar Soft Part
- Sarcoma, Ewing
- Severe Acute Respiratory Syndrome
- Small Cell Lung Carcinoma
- Syndrome
- Thrombocythemia, Essential
- Thrombocytosis
- Thymoma
- Thymus Neoplasms
- Triple Negative Breast Neoplasms
- Ulcer
Marketed drugs (1)
Recent trials (50)
- NCT07215832Lead sponsorN/A—
- NCT07200102CollaboratorPhase 1Dec 31, 2025
- NCT06399640CollaboratorPhase 1Aug 14, 2024
- NCT05980806Lead sponsorPhase 2Mar 31, 2024
- NCT05820763CollaboratorPhase 2Jan 31, 2024
- NCT05983276CollaboratorPhase 2Aug 28, 2023
- NCT05597345CollaboratorPhase 2Mar 31, 2023
- NCT05530421CollaboratorPhase 2Feb 1, 2023
- NCT05611931Lead sponsorPhase 3Nov 1, 2022
- NCT05170789CollaboratorPhase 2Apr 27, 2022
- NCT04984330CollaboratorEarly Phase 1Dec 31, 2021
- NCT04925193CollaboratorPhase 2Dec 31, 2021
- NCT04843579CollaboratorPhase 2Dec 31, 2021
- NCT04898894CollaboratorPhase 1Nov 15, 2021
- NCT05028348CollaboratorPhase 3Oct 31, 2021
Details
- Founded
- Natick, MA, US Jan 1, 2008
- First NDA
- Jul 3, 2019
- Last known activity
- Dec 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Accelerated approval